9IB Stock Overview
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Infant Bacterial Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr6.78 |
| 52 Week High | kr9.10 |
| 52 Week Low | kr6.58 |
| Beta | 1.01 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -30.03% |
| 5 Year Change | n/a |
| Change since IPO | -33.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9IB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -1.5% |
| 1Y | n/a | -30.8% | 0.9% |
Return vs Industry: Insufficient data to determine how 9IB performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 9IB performed against the German Market.
Price Volatility
| 9IB volatility | |
|---|---|
| 9IB Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9IB's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 9IB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 8 | Staffan Stromberg | www.ibtherapeutics.com |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants.
Infant Bacterial Therapeutics AB (publ) Fundamentals Summary
| 9IB fundamental statistics | |
|---|---|
| Market cap | €97.64m |
| Earnings (TTM) | -€10.57m |
| Revenue (TTM) | €6.61k |
Over9,999x
P/S Ratio-9.2x
P/E RatioIs 9IB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9IB income statement (TTM) | |
|---|---|
| Revenue | kr77.00k |
| Cost of Revenue | kr0 |
| Gross Profit | kr77.00k |
| Other Expenses | kr123.15m |
| Earnings | -kr123.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -9.14 |
| Gross Margin | 100.00% |
| Net Profit Margin | -159,828.57% |
| Debt/Equity Ratio | 0% |
How did 9IB perform over the long term?
See historical performance and comparison